Table 3.

Summary of preventive phase 3 clinical trials with sample size of more than thousand patients against severe acute respiratory syndrome coronavirus‐2 infection

Study identification number	Country	Sample size	Intervention assessed	Primary endpoint
NCT04333407	United Kingdom	3170	Aspirin; clopidogrel; rivaroxaban; atorvastatin; omeprazole	All‐cause mortality at 30 d after admission
Phase 3 trial	Sponsor‐Imperial College London
NCT04333732	Multicenter study	55 000	Different doses of chloroquine	Effectiveness in preventing laboratory‐confirmed symptomatic COVID‐19 in healthcare workers with repeated exposures to SARS‐CoV‐2
Phase 3 trial	Sponsor‐Bill and Melinda Gates Foundation
Crown coronation study
NCT04334967	USA	1250	Hydroxychloroquine	Percentages of enrolled patients needing hospitalization and mechanical ventilation at day 14
Phase 3 trial	Sponsor‐ Providence Health & Services
NCT04328467	USA	3500	Hydroxychloroquine	Outcome reported as the percent of participants in each arm who are COVID‐19‐free at the end of study treatment upto 12 wk
Phase 3 trial	Sponsor‐University of Minnesota
NCT04341441	USA	3500	Hydroxychloroquine daily vs weekly dosing	Measure the difference in new cases of COVID‐19 disease between randomized treatment arms at 8 wk
Phase 3 trial	Sponsor‐Henry Ford Health System
WHIP COVID study
NCT04342156	Singapore	1200	Hydroxychloroquine	Positive serology or reverse transcriptase (RT‐PCR) for COVID‐19 up until day 28
Phase 3 trial	Sponsor‐Tan Tock Seng Hospital
NCT04343001	United Kingdom	10 000	Aspirin, losartan, and simvastatin	Death upto 28 d from day of randomization
Phase 3 trial	Sponsor‐London School of Hygiene and Tropical Medicine
CRASH 19 study